Header

June 4, 2014

DynaMed Resident Focus is an outlet for residents to share recent evidence they find important with their peers. Residents who are members of the DynaMed community are eligible to participate. If interested, please email [email protected].

Addition of Renal Artery Stenting May Not Improve Cardiovascular and Renal Outcomes Compared to Medical Therapy Alone in Patients with Severe Atherosclerotic Renal Artery Stenosis

Reference: N Engl J Med 2014 Jan 2;370(1):13-22 (level 2 [mid-level] evidence)

About the Author

Mohamed Elshayeb, MD, is a second year internal medicine resident at Saint Joseph Mercy Hospital in Ann Arbor, Michigan. Faculty contribution by Dr. Ahmed Rehan, MD.

For more information about the residency program, visit the Saint Joseph Mercy Hospital webpage.

Drs. Elshayeb and Rehan have declared no financial or other competing interests.

Renal artery stenosis (RAS) may cause hypertension and worsening kidney function. Stenting of renal arteries has been proposed to decrease deterioration of kidney function and help control hypertension in patients with renal artery stenosis. It is hoped that this will decrease the risk of developing cardiac events such as myocardial infarction. However, randomized control trials have failed to show substantial benefit to blood pressure control or kidney function and there has been no study with the primary outcome being adverse cardiovascular or renal events.

The Cardiovascular Outcome in Renal Atherosclerotic Lesions (CORAL) trial was a multicenter, open-label, randomized, controlled trial to test the hypothesis that stenting for atherosclerotic RAS can prevent adverse cardiovascular and renal events. 947 participants (mean age 69 years) were randomly assigned to 2 groups: 467 participants in the stent plus medical therapy group and 480 participants in the medical therapy alone group. All patients had severe atherosclerotic renal artery stenosis and either systolic hypertension on 2 or more anti-hypertensive medications or an estimated glomerular filtration rate (GFR) of < 60 ml/min/1.73 m2. Medications used included candesartan with or without hydrochlorothiazide and combined atorvastatin-amlodipine. Blood pressure goal was less than140/90 in patients with no coexisting conditions and 130/80 in patients with diabetes mellitus or chronic kidney disease. The participants were followed for a median 43 months. The primary end point was a composite of death from any cardiovascular or renal cause and occurrence of major cardiovascular or renal events. Major cardiovascular events included myocardial infarction, stroke, or congestive heart failure requiring hospitalization for at least 12 hours with the need for intravenous therapy (vasodilators, diuretics, or inotropes) during hospitalization. Renal events included the need for permanent renal-replacement therapy and progressive renal insufficiency which is defined as 30% or more reduction in GFR for at least 60 days with no other attributable cause. Secondary clinical end points were the individual components of the primary outcome.

The primary outcome rates were not statistically different between groups. The primary composite outcome occurred in 35.1% in stent plus medications group compared to 35.8% in medical therapy alone group (P=0.58). In addition, no individual component of the primary composite outcome was statistically different between groups. Furthermore, there was no significant difference in all-cause mortality between groups.

The trial had some limitations. Severe stenosis was defined as either stenosis of at least 80% but less than 100% or stenosis of at least 60% but less than 80% plus 20 mm hg systolic pressure gradient. However, there is no consensus on the degree of stenosis for which intervention is recommended. Another limitation is this study cannot be applied to patients with fibromuscular dysplasia as these patients were excluded from the study.

In brief, superiority of stenting of stenotic atherosclerotic renal arteries plus medical therapy over medical therapy alone for prevention of cardiovascular and renal events in patients with renal artery stenosis was not demonstrated. Per the American College of Cardiology (ACC) and American Heart Association (AHA) recommendations, revascularization is indicated for patients with significant renal artery stenosis and either unexplained heart failure or unexplained pulmonary edema. Also, revascularization may be an option in patients with progressive chronic kidney disease with bilateral RAS or in patients with RAS and inadequately controlled hypertension. However, these recommendations may need to be modified given the CORAL study results.

For more information, see Renal artery stenosis in DynaMed.

Join Our Mailing List

DynaMed Contribution Opportunities

DynaMed Peer Review
Education for Clinicians in Training
Become a DynaMed Reviewer

Quick Links

Share with Colleagues
Previous Issues
DynaMed Free Trial
Send Comment to Editor

DynaMed EBM Focus

DynaMed EBM Focus, Issue 21:

CAM-S Severity Score May Help Predict 90-Day Mortality and Length of Hospital Stay in Hospitalized Patients ≥ 70 Years Old Without Delirium

DynaMed EBM Focus, Issue 22:

Topical Tetracaine for Home Use Not Associated With Delayed Corneal Healing or Increased Symptom Rates at 48 Hours in Patients With Corneal Abrasion

EBSCO Health Launches Pediatric Clinical Information Mobile App

PEMSoft Now Available For iPhone, iPad, and Android Devices

A mobile app designed specifically for pediatricians, emergency department physicians, physicians-in-training and other medical providers caring for children with acute illnesses and injury, is now available from EBSCO Health, the leading provider of clinical decision support solutions for the healthcare industry.

Designed by pediatricians, emergency physicians and other medical specialists, PEMSoft is a pediatric evidence-based point-of-care medical reference tool for hospitals, emergency departments, clinics, pediatric group practices, transport services, and medical schools. The vast content in PEMSoft addresses the entire spectrum of neonatal, infant, child, adolescent and young adult health. PEMSoft authors adhere to a strict evidence-based editorial policy focused on systematic identification, evaluation and consolidation of practice-changing clinical literature.

The PEMSoft Mobile app includes explicit step-by-step emergency critical care procedures, information about common pediatric signs and symptoms and content covering pediatric injuries and management approaches. More than 3,000 evidence-based pediatric topics and a similar number of medical illustrations, clinical images and videos are also available via the mobile app.

The PEMSoft Mobile App is accessible from both Apple and Android devices.

For more information and technical support, visit the PEMSoft Mobile Access page. To view the official press release, click here.

DynaMed Events

June 18, 2014 / 8am-12:30pm

Senior Deputy Editor Alan Ehrlich, MD, will be attending the Massachusetts Medical Society (MMS) CME Event and Conference on Medical Marijuana: Regs, Responsibilities & Communication, held at the MMS Headquarters at Waltham Woods in Waltham, Massachusetts. Representatives will be available to discuss peer review, mobile access, and free trial information.

Visit the MMS website to learn more about the event and for registration information.

If you would like to meet with a DynaMed representative at any of our conferences, please contact us at [email protected].